MegaMD KRX:133750KOSDAQ
메가엠디 · Korean news coverage and regulatory filings, organized.
In Q3 2026, MegaMD reported revenue of ₩8.7bn, down 6.2% year on year, and operating profit of ₩1.0bn. MegaMD (메가엠디) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
MegaMD today: up or down?
No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.
Upcoming dates as filed
- Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026
Dates MegaMD stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.
MegaMD quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q3 2026 | ₩8.7bn | -6.2% | ₩1.0bn margin 12.0% | ₩1.4bn |
| Q2 2026 | – | – | ₩995m | ₩1.6bn |
| Q1 2026 | ₩7.8bn | -7.1% | ₩150m margin 1.9% | ₩1.9bn |
| Q4 2025 derived | ₩7.1bn | +0.2% | −₩570m margin −8.0% | −₩609m |
| Q3 2025 | ₩9.3bn | -6.2% | ₩1.7bn margin 17.9% | ₩2.2bn |
| Q2 2025 | ₩9.8bn | -9.0% | ₩1.2bn margin 12.4% | ₩1.4bn |
| Q1 2025 | ₩8.4bn | -3.8% | −₩492m margin −5.9% | −₩194m |
| Q4 2024 derived | ₩7.1bn | +6.0% | −₩978m margin −13.7% | ₩368m |
MegaMD ranks #1109 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
MegaMD top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.